US4414209A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Micronized aerosol steroids
Assignee: Allen and Hanburys Ltd
•
Filing: 1977-06-13
•
Granted: 1983-11-08
•
Expires: 1997-06-13
Abstract
Abstract An antiinflammatory steroid exhibiting a tendency to crystal growth in suspension in aerosol propellants is contacted with a halogenated hydrocarbon to form a crystalline solvate, which, after removal of some or all of the propellant from the crystals, is reduced to a particle size permitting inhalation into the human bronchial system when dispersed as an aerosol, the micronized crystalline solvate not thereafter exhibiting crystal growth in the aerosol propellant. The solvate is a new composition of matter which has been characterized by I.R. spectra and the aerosol formulation prepared therefrom has valuable therapeutic properties, particularly in the treatment of asthma.
Inventors
- 👤 Peter B. Cook
- 👤 John H. Hunt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 11:21
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/008
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
99 words
An antiinflammatory steroid in the form of a crystalline solvate with a halogenated hydrocarbon or said crystalline solvate from which part or all of the halogenated hydrocarbon has been removed, wherein said halogenated hydrocarbon is a chloro or chlorofluoro hydrocarbon having 1 or 2 carbon atoms; said steroid is beclomethasone dipropionate, betamethasone-21-acetate-17-isobutyrate or 21-chloro-21-desoxybetamethasone-17-propionate, said steroid being stabilized with respect to further crystal growth in a chloro or chlorofluoro hydrocarbon solvent having 1 or 2 carbon atoms and the particle size of substantially all of the steroid material being such as to permit inhalation into the human bronchial system.
Claim 2
Dependent Claim
99 words
An antiinflammatory steroid in the form of a crystalline solvate with a halogenated hydrocarbon or said crystalline solvate from which part or all of the halogenated hydrocarbon has been removed, wherein said halogenated hydrocarbon is a chloro or chlorofluoro hydrocarbon having 1 or 2 carbon atoms; said steroid is beclomethasone dipropionate, betamethasone-21-acetate-17-isobutyrate or 21-chloro-21-desoxybetamethasone-17-propionate, said steroid being stabilized with respect to further crystal growth in a chloro or chlorofluoro hydrocarbon solvent having 1 or 2 carbon atoms and the particle size of substantially all of the steroid material being such as to permit inhalation into the human bronchial system.
Claim 3
Dependent Claim
19 words
A steroid material as claimed in claim 1 in which the particle size is not greater than 20 microns.
Claim 4
Dependent Claim
19 words
A steroid material as claimed in claim 1 in which the particle size is from 2 to 5 microns.
Claim 5
Dependent Claim
15 words
A steroid material as claimed in claim 1 in which the steroid is beclomethasone dipropionate.
Claim 6
Dependent Claim
15 words
A steroid material as claimed in claim 4 in which the halogenated hydrocarbon is trichloromonofluoromethane.
Claim 7
Dependent Claim
15 words
A steroid material as claimed in claim 5 in which the halogenated hydrocarbon is difluorodichloromethane.
Claim 8
Dependent Claim
17 words
A steroid material as claimed in claim 32 in which the steroid is betamethasone 21-acetate-17-isobutyrate or 21-chloro-21-desoxy-betamethasone-17-propionate.
Claim 9
Dependent Claim
29 words
A steroid material as claimed in claim 4 in the form of a solvate with trichloromonofluoromethane having the I.R. spectrum as shown in FIG. 1 of the accompanying drawings.
Claim 10
Dependent Claim
32 words
A steroid material as claimed in claim 7 in the form of a solvate of betamethasone 21-acetate-17-isobutyrate with trichloromonofluoromethane having the I.R. spectrum as shown in FIG. 2 of the accompanying drawings.
Claim 11
Dependent Claim
31 words
A steroid material as claimed in claim 7 in the form of a solvate of 21-chloro-21-desoxy-betamethasone-17-propionate with chloroform having the I.R. spectrum as shown in FIG. 4 of the accompanying drawings.
References Cited (Backward Citations)
US3312590A
Cited
US3721687A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-07 | 1987-05-09 | 1987-11-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-07 | 1991-05-09 | 1991-11-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-07 | 1995-05-09 | 1995-11-08 | $7700.00 | Window Closed / Lapsed |